Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.
Cristina Varallo-RodriguezCraig W FreyerEvelena P OntiverosElizabeth A GriffithsEunice S WangMeir Wetzler
Published in: Expert opinion on orphan drugs (2015)
We propose that future studies should explore the use of bosutinib in Ph+ ALL due to its multi-kinase inhibitory activity and its relatively long-term safety compared to other second and third generation TKIs.